News

The company has also launched a large scale study of DXL625 with primates, designed to evaluate toxicity and pharmokinetics, enabling the company to move the product to the

The novel peptide CGEN-25008 has been shown to slow the growth of human non-small cell lung cancer cells and other malignant cell lines including breast, prostate, colon and

The closing follows completion of the US Federal Trade Commission’s review of the license agreement under the Hart-Scott-Rodino Act and the issuance of a consent order to permit

According to the company, the patented technology effectively solubilizes pharmaceutical compounds in micellar formulations containing fatty acids or fatty alcohols. Further, it addresses many excipient related safety issues,

SemBioSys submitted the application in July 2008 to the FDA, which has now completed its review of the file. SemBioSys intends to conduct the Phase I/II insulin trial

The new drug application (NDA) submission is based on a comprehensive Phase III clinical development program for Solzira in patients with moderate-to-severe primary restless legs syndrome (RLS), including

The company has already developed a proprietary, three-month formulation of goserelin for which a Phase I/II clinical program in prostate cancer patients was initiated in July 2008. Ambrilia’s

Sirtuins are a family of enzymes which regulate the aging process and have been the subject of extensive research. While SIRT1 – the founding member of this class

Galantamine hydrobromide is indicated for mild to moderate dementia associated with Alzheimer’s disease.